Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Although mucosal healing (MH) is acknowledged as the treatment target in the treat-to-target era, there are limitations on repeated endoscopic examinations, especially in pediatric patients. We aimed to investigate whether fecal calprotectin (FC) could serve as a surrogate marker for the assessment of MH in pediatric patients with Crohn’s disease (CD) who have achieved sustained clinical remission (CR) while treated with anti-tumor necrosis factor (TNF) agents. Methods: This multicenter retrospective cross-sectional study included pediatric CD patients who had sustained a CR for at least 6 months with anti-TNF agents and who simultaneously underwent ileocolonoscopy and FC tests during follow-up. MH was defined as the absence of any ulcer on ileocolonoscopy. Results: A total of 131 patients were included in this study. MH was observed in 87 patients (66.7%). The FC level was significantly lower in patients with MH than in those without MH (median 49.0 mg/kg vs 599.0 mg/kg; p<0.001). According to the multivariate logistic regression analysis, FC was the only factor associated with MH (odds ratio, 0.62; 95% confidence interval [CI], 0.52 to 0.73; p<0.001). According to the receiver operating characteristic curve analysis, the optimal cutoff value for FC for the association with MH was <140 mg/kg (area under the curve 0.890, 95% CI 0.829 to 0.951, sensitivity 78.2%, specificity 88.6%, p<0.001). Conclusions: FC was associated with MH in pediatric patients with CD who had achieved a sustained CR for at least 6 months with anti-TNF agents. In these patients, FC can be used to stratify patients and guide decisions regarding ileocolonoscopy in the treat-to-target era.
Abstract
Background/Aims: Although mucosal healing (MH) is acknowledged as the treatment target in the treat-to-target era, there are limitations on repeated endoscopic examinations, especially in pediatric patients. We aimed to investigate whether fecal calprotectin (FC) could serve as a surrogate marker for the assessment of MH in pediatric patients with Crohn’s disease (CD) who have achieved sustained clinical remission (CR) while treated with anti-tumor necrosis factor (TNF) agents. Methods: This multicenter retrospective cross-sectional study included pediatric CD patients who had sustained a CR for at least 6 months with anti-TNF agents and who simultaneously underwent ileocolonoscopy and FC tests during follow-up. MH was defined as the absence of any ulcer on ileocolonoscopy. Results: A total of 131 patients were included in this study. MH was observed in 87 patients (66.7%). The FC level was significantly lower in patients with MH than in those without MH (median 49.0 mg/kg vs 599.0 mg/kg; p<0.001). According to the multivariate logistic regression analysis, FC was the only factor associated with MH (odds ratio, 0.62; 95% confidence interval [CI], 0.52 to 0.73; p<0.001). According to the receiver operating characteristic curve analysis, the optimal cutoff value for FC for the association with MH was <140 mg/kg (area under the curve 0.890, 95% CI 0.829 to 0.951, sensitivity 78.2%, specificity 88.6%, p<0.001). Conclusions: FC was associated with MH in pediatric patients with CD who had achieved a sustained CR for at least 6 months with anti-TNF agents. In these patients, FC can be used to stratify patients and guide decisions regarding ileocolonoscopy in the treat-to-target era.
참고문헌 (35)
- Baumgart DC, "Inflammatory bowel disease : clinical aspects and established and evolving therapies", Lancet, 369, pp.1641~1657 (2007)
- Thia KT, "Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort", Gastroenterology, 139, pp.1147~1155 (2010)
- 김승, "Surgery in Pediatric Crohn’s Disease: Indications, Timing and Post-Operative Management", Pediatric Gastroenterology, Hepatology & Nutrition, 20(1), pp.14~21 (2017), 대한소아소화기영양학회
- Ben Kang, "Early Biologic Treatment in Pediatric Crohn’s Disease: Catchingthe Therapeutic Window of Opportunity in Early Disease by Treat-to-Target", Pediatric Gastroenterology, Hepatology & Nutrition, 21(1), pp.1~11 (2018), 대한소아소화기영양학회
- Kang B, "Mucosal healing in paediatric patients with moderate-to-severe luminal Crohn’s disease under combined immunosuppression : escalation versus early treatment", J Crohns Colitis, 10, pp.1279~1286 (2016)
- Ben Kang, "Korean Children and Adolescents with Crohn's Disease Are More Likely to Present with Perianal Fistulizing Disease at Diagnosis Compared to Their European Counterparts", Pediatric Gastroenterology, Hepatology & Nutrition, 23(1), pp.49~62 (2020), 대한소아소화기영양학회[DOI]
- Bouguen G, "Treat to target : a proposed new paradigm for the management of Crohn’s disease", Clin Gastroenterol Hepatol, 13, pp.1042~1050 (2015)
- Peyrin-Biroulet L, "Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE) : determining therapeutic goals for treat-to-target", Am J Gastroenterol, 110, pp.1324~1338 (2015)
- D’Haens G, "Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease", Inflamm Bowel Dis, 18, pp.2218~2224 (2012)
- Sipponen T, "Crohn’s disease activity assessed by fecal calprotectin and lactoferrin : correlation with Crohn’s disease activity index and endoscopic findings", Inflamm Bowel Dis, 14, pp.40~46 (2008)
- Schoepfer AM, "Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease(SES-CD)than CRP, blood leukocytes, and the CDAI", Am J Gastroenterol, 105, pp.162~169 (2010)
- Zubin G, "Predicting endoscopic Crohn’s disease activity before and after induction therapy in children : a comprehensive assessment of PCDAI, CRP, and fecal calprotectin", Inflamm Bowel Dis, 21, pp.1386~1391 (2015)
- Weinstein-Nakar I, "Associations among mucosal and transmural healing and fecal level of calprotectin in children with Crohn’s disease", Clin Gastroenterol Hepatol, 16, pp.1089~1097 (2018)
- Choon Jin Ooi, "Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia", Intestinal research, 17(3), pp.285~310 (2019), 대한장연구학회[DOI]
- Levine A, "ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents", J Pediatr Gastroenterol Nutr, 58, pp.795~806 (2014)
- Levine A, "Pediatric modification of the Montreal classification for inflammatory bowel disease : the Paris classification", Inflamm Bowel Dis, 17, pp.1314~1321 (2011)
- Turner D, "Appraisal of the pediatric Crohn’s disease activity index on four prospectively collected datasets : recommended cutoffvalues and clinimetric properties", Am J Gastroenterol, 105, pp.2085~2092 (2010)
- Daperno M, "Development and validation of a new, simplified endoscopic activity score for Crohn’s disease : the SES-CD", Gastrointest Endosc, 60, pp.505~512 (2004)
- Ma C, "Update on C-reactive protein and fecal calprotectin : are they accurate measures of disease activity in Crohn’s disease?", Expert Rev Gastroenterol Hepatol, 13, pp.319~330 (2019)
- Kang B, "Infliximab trough levels are associated with mucosal healing during maintenance treatment with infliximab in paediatric Crohn’s disease", J Crohns Colitis, 13, pp.189~197 (2019)
- Kang B, "Subtherapeutic infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab cessation in paediatric-onset Crohn’s disease patients treated with combined immunosuppressive therapy", J Crohns Colitis, 12, pp.644~652 (2018)
- Ma C, "Advances in therapeutic drug monitoring for small-molecule and biologic therapies in inflammatory bowel disease", Curr Treat Options Gastroenterol, 17, pp.127~145 (2019)
- Mendall MA, "Faecal calprotectin : factors affecting levels and its potential role as a surrogate marker for risk of development of Crohn’s Disease", BMC Gastroenterol, 16, pp.126~ (2016)
- Theede K, "Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis", Inflamm Bowel Dis, 22, pp.1042~1048 (2016)
- Heida A, "Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease : a systematic review and practical guide", Inflamm Bowel Dis, 23, pp.894~902 (2017)
- Ferreiro-Iglesias R, "Accuracy of consecutive fecal calprotectin measurements to predict relapse in inflammatory bowel disease patients under maintenance with anti-TNF therapy : a prospective longitudinal cohort study", J Clin Gastroenterol, 52, pp.229~234 (2018)
- Canani RB, "Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease", Dig Liver Dis, 40, pp.547~553 (2008)
- Patel A, "Fecal calprotectin levels predict histological healing in ulcerative colitis", Inflamm Bowel Dis, 23, pp.1600~1604 (2017)
- Zittan E, "Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn’s disease", Inflamm Bowel Dis, 22, pp.623~630 (2016)
- Kostas A, "Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease", World J Gastroenterol, 23, pp.7387~7396 (2017)
- Mosli MH, "C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients : a systematic review and meta-analysis", Am J Gastroenterol, 110, pp.802~819 (2015)
- Cozijnsen MA, "Development and validation of the mucosal inflammation noninvasive index for pediatric Crohn’s disease", Clin Gastroenterol Hepatol, 18, pp.133~140 (2020)
- Ebby George Simon, "Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s disease?: a systematic review", Intestinal research, 17(2), pp.160~170 (2019), 대한장연구학회[DOI]
- Gecse KB, "Impact of disease location on fecal calprotectin levels in Crohn’s disease", Scand J Gastroenterol, 50, pp.841~847 (2015)
- Prell C, "Comparison of three tests for faecal calprotectin in children and young adults : a retrospective monocentric study", BMJ Open, 4, pp.e004558~ (2014)